Evidence map›Paper›PMID 28910345›Full record

Trial reportPloS one2017

Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.

Marilesia Ferreira de Souza, Hellen Kuasne, Mateus de Camargo Barros-Filho, Heloísa Lizotti Cilião, Fabio Albuquerque Marchi, Paulo Emilio Fuganti, Alexandre Rossi Paschoal, Silvia Regina Rogatto, Ilce Mara de Syllos Cólus

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Urinary microRNAs expression in prostate cancer diagnosis: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Marilesia Ferreira de SouzaGeneral Biology Department, State University of Londrina, Londrina, Paraná, Brazil.
Hellen KuasneCIPE, AC Camargo Cancer Center, São Paulo, São Paulo, Brazil.
Mateus de Camargo Barros-FilhoCIPE, AC Camargo Cancer Center, São Paulo, São Paulo, Brazil.
Heloísa Lizotti CiliãoGeneral Biology Department, State University of Londrina, Londrina, Paraná, Brazil.
Fabio Albuquerque MarchiCIPE, AC Camargo Cancer Center, São Paulo, São Paulo, Brazil.
Paulo Emilio FugantiLondrina Cancer Hospital, Londrina, Paraná, Brazil.
Alexandre Rossi PaschoalDepartment of Computing, Federal University of Technology-Paraná, UTFPR, Cornélio Procópio, Paraná, Brazil.
Silvia Regina RogattoCIPE, AC Camargo Cancer Center, São Paulo, São Paulo, Brazil.
Ilce Mara de Syllos CólusGeneral Biology Department, State University of Londrina, Londrina, Paraná, Brazil.
AC Camargo Hospital · BRUniversidade Estadual de Londrina · BREntomological Society of Brazil · BRUniversidade Tecnológica Federal do Paraná · BRUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating nucleic acids are found in free form in body fluids and may serve as minimally invasive tools for cancer diagnosis and prognosis. Only a few studies have investigated the potential application of circulating mRNAs and microRNAs (miRNAs) in prostate cancer (PCa). The Cancer Genome Atlas (TCGA) database was used for an in silico analysis to identify circulating mRNA and miRNA as potential markers of PCa. A total of 2,267 genes and 49 miRNAs were differentially expressed between normal and tumor samples. The prediction analyses of target genes and integrative analysis of mRNA and miRNA expression revealed eleven genes and eight miRNAs which were validated by RT-qPCR in plasma samples from 102 untreated PCa patients and 50 cancer-free individuals. Two genes, OR51E2 and SIM2, and two miRNAs, miR-200c and miR-200b, showed significant association with PCa. Expression levels of these transcripts distinguished PCa patients from controls (67% sensitivity and 75% specificity). PCa patients and controls with prostate-specific antigen (PSA) ≤ 4.0 ng/mL were discriminated based on OR51E2 and SIM2 expression levels. The miR-200c expression showed association with Gleason score and miR-200b, with bone metastasis, bilateral tumor, and PSA > 10.0 ng/mL. The combination of circulating mRNA and miRNA was useful for the diagnosis and prognosis of PCa.

Indexed as

Basic Helix-Loop-Helix ProteinsNeoplasm ProteinsReceptors, OdorantAgedBiomarkers, TumorBone NeoplasmsHumansKallikreinsMaleMicroRNAsMiddle AgedNeoplasm MetastasisProstate-Specific AntigenProstatic NeoplasmsReverse Transcriptase Polymerase Chain ReactionRNA, MessengerBasic Helix-Loop-Helix ProteinsBiomarkers, TumorKallikreinsKLK3 protein, humanMicroRNAsMIRN200 microRNA, humanNeoplasm ProteinsOR51E2 protein, humanProstate-Specific AntigenReceptors, OdorantRNA, MessengerRNA, NeoplasmSIM2 protein, human

Identifiers

PMID28910345
PMCPMC5598937
OpenAlexW2755834791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.